

Supplementary material

Methods

Exclusion criteria:

- Patients with a positive PCR for CoV-2 admitted for a primary diagnosis other than ARDS were excluded.

Tocilizumab treatment criteria

Fulfillment of all of the following criteria:

1. Rising oxygen requirements with at least 5 L/minute on oxygen mask to maintain SpO₂ at 94%;
2. Day seven or later from symptom onset;
3. Hyperinflammation characterized by at least one of the following: CRP > 100 mg/L or doubled in the last 24hrs, lactate dehydrogenase (LDH) > 8 µkat/L, IL-6 > 40 ng/L, D-Dimer > 2mg/L or rising, high sensitivity troponin T > 15 ng/L or ferritin > 500 µg/L;
4. No contraindication to tocilizumab (known hypersensitivity, diverticular disease or history of intestinal perforation, aspartate and alanine aminotransferase levels (ASAT/ALAT) at > 5 times of the upper limit of normal, neutropenia with < 500 cells/mm³, thrombocytopenia < 50 cells/mm³).

Routine care

Routine care consisted in supportive ARDS care as per Surviving Sepsis Campaign guidelines and was provided to all patients (1). General admission criteria to ICU did not differ between

treatment and control group. Routine supportive ARDS care was provided to all patients. No adjunctive immunomodulatory or antiviral treatment was routinely administered.

Selection of patients for the control group

Inclusion of controls was performed by co-investigators who were not directly involved in the care of these patients and thus unaware of their clinical outcome to avoid selection bias. Patients were eligible if they were admitted to ICU with COVID-19 and ARDS but

- did not fulfill the above tocilizumab treatment criteria or
- were not considered for anti-IL-6 treatment by the admitting physician.

Outcome definitions:

Freedom from mechanical ventilation was defined as no residual positive pressure support in surviving patients (extubated, tracheostomized or decannulated). The ordinal scale was used in accordance with WHO recommendations, merging category 6 and 7 into one as described elsewhere (2). Sepsis on ICU was defined as the finding of an obligate pathogen in blood cultures mandating antibiotic treatment or the finding of a facultative pathogen in ≥ 2 separate blood cultures with concomitant pyrexia and/or a rise in WBC count or CRP. For patients treated with tocilizumab this requirement was waived due to the blockage of the IL-6 pathway affecting CRP production and pyrexia. Given the underlying severe ARDS, ventilator-associated pneumonia (VAP) was pragmatically defined as a secondary rise in inflammatory parameters with findings of a significant amount (CFU $>10^5$ /ml) of a potential respiratory pathogen upon tracheal aspiration or bronchoalveolar lavage mandating antibiotic treatment. Pulmonary embolism was defined as pulmonary arterial embolism verified by pulmonary CT angiogram.

Data collection

Data was collected from the electronic health record system (TakeCare®) of the institution and recorded in a standardized electronic case report form (eCRF). Detailed demographic data, comorbidities as well as clinical data upon admission to the hospital were collected from all patients. Laboratory data was recorded upon admission to ICU to assess for baseline differences in the severity of illness between groups. PaO₂ for the assessment of ARDS severity was derived from arterial blood gases that were also available on general wards and measured in kPa. FiO₂ was estimated depending on the delivery method or directly recorded when administered via high-flow nasal cannula.

Statistical analysis

Continuous variables were reported as median and interquartile range (IQR) and compared using the Mann-Whitney test or t-test, as appropriate. Categorical variables were reported as frequencies with percentages and compared using the chi-squared test or Fisher's exact test, as appropriate. Missing data (consistently below 5%) was analyzed for continuous variables and multiple imputation was performed. Sample size calculation was based on available subjects in the treatment group (n = 29). With published data showing a 21-day mortality rate of 44% among comparable critically ill patients with COVID-19 (3), we postulated a 50% all-cause mortality at 30 days in controls and chose a 2:1 control subject ratio in order to be able to detect a mortality of 15% in the tocilizumab group at a power of 0.8 and a type I error rate of 0.05 using a chi-squared test. A two-sided $\alpha < 0.05$ was considered statistically significant. Survival analysis was performed for 30-day all cause mortality and freedom from mechanical ventilation by the Kaplan–Meier method and compared using a log-rank test. The hazard ratio of the risk of each of the survival endpoints at day 30 was estimated using a Cox proportional hazards regression model. R version 4.0.0 was used for descriptive analysis and propensity score

calculation. STATA version 16.1 (StataCorp, College Station, TX, USA) was used for survival analysis.

Propensity score generation

The propensity score was obtained using a multivariate logistic regression to predict the probability to receive tocilizumab controlling for pre-specified covariates (age, diabetes, hypertension, obesity, D-dimer, interleukin-6, troponin T and PaO₂/FiO₂ ratio). The two groups were matched using a 1:1 nearest neighbor matching algorithm without replacement and a caliper of 0.2 of the standard deviation of the PS on the logit scale. Covariate balance between the two groups was assessed after matching, and we considered an absolute standardized difference less than 0.1 as evidence of balance. Then, clinical endpoints were compared between the tocilizumab and control group within the matched dataset. Within R version 4.0.0, the packages “MatchIt” and “cobalt” were used.

Results

Adjunctive antiviral treatment

Less than 10% of patients (equally distributed in both groups) received chloroquine phosphate during 1-2 days before admission to ICU during the first week of the study period.

Characteristics of deceased patients

Median time to death was eight days in treated patients (IQR 5-12.5) and 14 days (IQR 10-19, $p = 0.15$) in the control group. Median age among deceased patients was 70 (IQR 62-75) in the TCZ group and 67 (IQR 52-72) in the control group, respectively.

Supplementary references

1. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Oczkowski S, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). *Intensive Care Medicine*. 2020;104.
2. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet*. 2020 May 16;395(10236):1569–78.
3. Cavalli G, Luca GD, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. *The Lancet Rheumatology* [Internet]. 2020 May 7 [cited 2020 May 13];0(0). Available from: [https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913\(20\)30127-2/abstract](https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30127-2/abstract)

Supplementary table

Suppl. table 1: Baseline characteristics, clinical and laboratory parameters.

Variable	Native cohort (n = 87)			Matched cohort (n = 44)		
	Tocilizumab (n = 29)	Control (n = 58)	p-value	Tocilizumab (n = 22)	Control (n = 22)	p-value
Patient characteristics						
Age	58.0 [49.0, 63.0]	55.0 [52.0, 64.8]	0.91	60.5 [48.5, 64.0]	59.5 [54.0, 66.5]	0.46
Male gender	28 (96.6)	45 (77.6)	0.05	21 (95.5)	17 (77.3)	0.19
Current smoker	4 (13.8)	13 (22.4)	0.50	4 (18.2)	6 (27.3)	0.72
Arterial hypertension	10 (34.5)	21 (36.2)	1.00	8 (36.4)	9 (40.9)	1.00
Cardiovascular disease	2 (6.9)	4 (6.9)	1.00	2 (9.1)	1 (4.5)	1.00
Diabetes	5 (17.2)	15 (25.9)	0.53	4 (18.2)	3 (13.6)	1.00
Asthma / COPD	2 (6.9)	5 (8.6)	1.00	2 (9.1)	0 (0.0)	0.47
Chronic kidney disease	1 (3.4)	0 (0.0)	0.72	1 (4.5)	0 (0.0)	1.00
BMI (kg/m ²)	27.0 [26.0, 29.0]	29.0 [26.2, 31.8]	0.02	28.0 [26.0, 29.0]	28.5 [25.0, 29.0]	0.79
Hospital admission status						
Oxygen saturation (%)	87.0 [82.0, 90.0]	88.0 [80.0, 92.0]	0.49	87.0 [82.2, 89.8]	83.0 [80.0, 92.0]	0.97
Respiratory rate (/min)	28.0 [24.0, 33.0]	27.0 [22.0, 30.0]	0.32	28.0 [25.0, 33.0]	26.0 [21.2, 30.0]	0.28

ICU admission status						
PaO2 (kPa) / FiO2	10.3 [8.6, 12.8]	10.1 [8.9, 11.6]	0.73	10.2 [8.7, 12.5]	10.3 [9.0, 11.6]	0.94
ARDS class (Berlin) = moderate	7 (24.1)	4 (6.9)	0.05	4 (18.2)	2 (9.1)	0.41
ARDS class (Berlin) = severe	22 (75.9)	54 (93.1)		18 (81.8)	20 (90.9)	
CRP (mg/L)	270.0 [232.0, 346.0]	198.5 [132.5, 263.0]	<0.01	276.5 [237.8, 342.0]	227.0 [136.2, 299.2]	0.06
LDH (μkat/L)	9.6 [8.1, 11.0]	8.2 [6.7, 10.6]	0.08	9.9 [8.2, 11.3]	9.5 [6.7, 11.2]	0.45
Ferritin (μg/L)	1939.0 [1305.0, 2405.0]	1546.0 [1074.2, 2489.8]	0.33	1710.0 [924.8, 2366.8]	1603.5 [1253.0, 2521.8]	0.87
D-Dimer (mg/L)	2.7 [0.8, 4.6]	1.2 [0.7, 3.0]	0.19	2.8 [0.9, 4.6]	1.4 [0.9, 3.5]	0.65
Lymphocyte count (cells/mm ³)	0.8 [0.6, 0.9]	1.0 [0.7, 1.1]	0.02	0.8 [0.6, 0.9]	0.9 [0.7, 1.1]	0.30
Interleukin-6 (ng/L)	351.0 [154.0, 1193.0]	180.5 [105.8, 335.2]	0.02	302.0 [141.2, 763.0]	228.5 [150.8, 452.0]	0.64
Troponin T (ng/L)	13.0 [10.0, 17.0]	11.0 [8.2, 19.0]	0.33	13.0 [10.0, 19.2]	16.0 [11.0, 19.8]	0.69
Time intervals (in days)						
Symptom onset to ICU admission	8.0 [7.0, 13.0]	10.0 [8.0, 13.8]	0.14	9.0 [7.0, 12.8]	11.0 [9.2, 14.8]	0.11
Admission to hospital to ICU admission	1.0 [1.0, 2.0]	1.0 [0.0, 3.0]	0.73	2.0 [1.0, 2.8]	1.0 [0.0, 3.0]	0.44
ICU admission to intubation	0.0 [0.0, 1.0]	0.0 [0.0, 1.0]	0.34	0.0 [0.0, 1.0]	0.0 [0.0, 1.0]	0.81
Symptom onset to tocilizumab	11.0 [8.0, 14.0]	NA	NA	10.5 [8.0, 13.5]	NA	NA
Tocilizumab to ICU admission	1.0 [0.0, 2.0]	NA	NA	0.5 [0.0, 2.0]	NA	NA
Tocilizumab on ICU	26 (89.7)	0 (0.0)	<0.01	20 (90.9)	0 (0.0)	<0.01

Adjunctive immunomodulatory treatment^c						
Steroids on ICU \leq d14	4 (13.8)	13 (22.4)	0.50	3 (13.6)	3 (13.6)	1.00
Steroids on ICU > d14	4 (13.8)	10 (17.2)	0.92	2 (9.1)	5 (22.7)	0.41
Intravenous immunoglobulins	3 (10.3)	6 (10.3)	1.00	2 (9.1)	3 (13.6)	1.00

Data are presented in median [interquartile range] or in absolute numbers (percentage). The matched cohort on the right represents the cohort matched my propensity score.

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; PaO₂, partial arterial pressure of oxygen; FiO₂, fraction of inspired oxygen; ARDS, acute respiratory distress syndrome; CRP, C-reactive protein; LDH, lactate dehydrogenase; IQR, interquartile range; ICU intensive care unit; NIV, non-invasive ventilation; suppl. supplementary;

^c Given on a case-by-case basis in case of septic shock or failure to improve on the ventilator after \geq 7 days.

Suppl. table 2: Outcomes.

Variable	Native cohort (n = 87)			PS-matched cohort (n = 44)		
	Tocilizumab (n = 29)	Control (n = 58)	p-value	Tocilizumab (n = 22)	Control (n = 22)	p-value
All patients						
30-day all cause mortality	5 (17.2)	19 (32.8)	0.20	5 (22.7)	7 (31.8)	0.73
Intubation and ventilation	24 (82.8)	53 (91.4)	0.41	18 (81.8)	21 (95.5)	0.34
Alive, off the ventilator (day 30)	22 (75.9)	31 (53.4)	0.07	16 (72.7)	10 (45.5)	0.13
Alive, no suppl. O2 (day 30)	21 (72.4)	20 (34.5)	<0.01	15 (68.2)	4 (18.2)	<0.01
Ordinal scale day 30 (%)			0.03			0.02
- Dead (1)	5 (17.2)	19 (32.8)		5 (22.7)	7 (31.8)	
- On ventilator (2)	2 (6.9)	8 (13.8)		1 (4.5)	5 (22.7)	
- NIV (3)	0 (0.0)	5 (8.6)		0 (0.0)	3 (13.6)	
- Hospitalized with suppl. oxygen (4)	1 (3.4)	6 (10.3)		1 (4.5)	3 (13.6)	
- Hospitalized, no suppl. oxygen (5)	4 (13.8)	6 (10.3)		3 (13.6)	1 (4.5)	
- Discharged (6)	17 (58.6)	14 (24.1)		12 (54.5)	3 (13.6)	
Survivors						
Ventilator-free days ^a	19.0 [12.5, 20.0]	9.0 [0.0, 18.5]	0.04	19.0 [13.0, 20.0]	4.0 [0.0, 12.0]	0.01
Length of stay in ICU (days)	12.0 [6.8, 17.2]	20.0 [9.8, 30.0]	0.04	11.0 [6.0, 17.0]	30.0 [18.5, 30.0]	<0.01
Length of stay in hospital (days)	20.5 [16.5, 30.0]	30.0 [21.5, 30.0]	0.04	20.0 [17.0, 30.0]	30.0 [30.0, 30.0]	0.01

ICU-related complications						
Renal replacement therapy ^b	4 (13.8)	14 (24.1)	0.40	2 (9.1)	6 (27.3)	0.24
- GFR upon ICU admission	90.0 [79.0, 90.0]	87.5 [77.0, 90.0]	0.90	85.5 [67.0, 90.0]	79.0 [70.2, 90.0]	0.38
- Last GFR ^c	90.0 [75.0, 90.0]	76.5 [17.0, 90.0]	0.03	90.0 [39.8, 90.0]	69.5 [18.8, 90.0]	0.13
Blood stream infection	5 (17.2)	14 (24.1)	0.65	4 (18.2)	6 (27.3)	0.72
Ventilator-associated pneumonia	6 (20.7)	19 (32.8)	0.36	5 (22.7)	8 (36.4)	0.51
Pulmonary embolism	6 (20.7)	13 (22.4)	1.00	4 (18.2)	6 (27.3)	0.72

Data are presented in median [interquartile range] or in absolute numbers (percentage).

Abbreviations: GFR glomerular filtration rate; suppl. supplementary; ICU intensive care unit; NIV, non-invasive ventilation;

a Calculated in survivors who received mechanical ventilation (n (tocilizumab/controls) = 19 / 34 and 13 / 14, respectively).

b Continuous or intermittent for at least 24h.

c Upon last follow-up (30 days, death or discharge if \leq 30 days).